Roche's Actemra has been in high demand since its ... 150 mg or 200 mg pre-filled syringes or auto-injectors – will be short until early 2022 based on current demand. Back in August, Roche's ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Roche's arthritis drug Actemra has become a key treatment for people with severe COVID-19, leading to shortages, and the World Health Organisation (WHO) wants the company to ensure that supplies ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra ... well as in a single-dose prefilled syringe (162mg/0.9mL) and a single ...